Abstract
Myelosuppression is a major symptom in the acquired immunodeficiency syndrome (AIDS). Moreover zidovudine, an anti-retroviral drug used to treat AIDS patients has myelosuppressive side effects. Therefore treatment with IL-3, a multi-lineage hemopoietic growth factor may be beneficial for zidovudine-treated individuals. In this study we examined the effect of IL-3 on human immunodeficiency virus (HIV) expression. The proliferative response to rIL-3 and the effects on the replication of the monocytotropic HIV variant. HTLV-III Ba-L, in the absence or presence of the anti-retroviral drug zidovudine was studied in purified human peripheral blood monocytes. Zidovudine concentrations sufficient for complete inhibition of HIV replication did not affect rIL-3 induced monocyte proliferation. Although rIL-3, like rGM-CSF, was able to augment HIV expression in monocytes. it did not interfere with the anti-retroviral activity of zidovudine. These data indicate that rIL-3 is a potential candidate for use in myelosupportive therapy in AIDS patients treated with anti-retroviral drugs. © 1990 by The American Society of Hematology.
Cite
CITATION STYLE
Schuitemaker, H., Kootstra, N. A., Van Oers, M. H. J., Van Lambalgen, R., Tersmette, M., & Miedema, F. (1990). Induction of monocyte proliferation and HIV expression by IL-3 does not interfere with anti-viral activity of zidovudine. Blood, 76(8), 1490–1493. https://doi.org/10.1182/blood.v76.8.1490.bloodjournal7681490
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.